Drug Trial Radar · NCT02089048
Auranofin PK Following Oral Dose Administration
Last checked: Nov 20, 2026Latest source record: Apr 28, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
15
Actual
Start
Apr 2, 2014
Primary completion
Sep 9, 2014
Study completion May 13, 2015
Sponsor
- Sponsor type
- NIH
- First posted
- Mar 17, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Phase I, open-label study in 15 healthy adult subjects receive 6 mg of auranofin orally once every 24 hours for 7days. Blood samples will be taken for 17 weeks following the last dose of auranofin for determination of terminal phase pharmacokinetic parameters. Stool samples will also be obtained for the measurement of gold.
Conditions
- Amoebiasis
Interventions
AuranofinDrug
Auranofin is a gold-containing chemical salt available as 3mg capsules. Cohort 1 receives 6mg oral dose of auranofin once every 24 hours for 7 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Plasma concentrations of gold following 7 once daily doses of auranofinTime frame: Up to Day 126
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Quintiles Phase I Services - Overland Park
Overland Park, Kansas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.